Orthopedic Surgery was Conmed’s largest revenue line in fiscal 2017, bringing in $428.94M of $796.39M (54%).
| Product Lines | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|
| Orthopedic Surgery | $402.75M | $444.98M | $422.10M | $428.94M | |||
| General Surgery | $279.36M | $274.19M | $341.42M | $367.45M | |||
| Surgical Visualization | $57.95M | — | — | — | |||
| Total | $740.06M | $719.17M | $763.52M | $796.39M |
Conmed brought in $796.39M from its two revenue lines in fiscal 2017, the year ended December 31, 2017. That was up 4.3% from $763.52M in fiscal 2016. Orthopedic Surgery was the largest at $428.94M (53.9%), ahead of General Surgery at $367.45M (46.1%).
Compared with fiscal 2016, General Surgery grew 7.6% to $367.45M and Orthopedic Surgery grew 1.6% to $428.94M.
Conmed stopped reporting Surgical Visualization as a separate revenue line after fiscal 2014, when it brought in $57.95M.
Conmed Linvatec was Conmed’s largest segment in fiscal 2010, bringing in $288.42M of $571.44M (50%).
| Business Segments | FY 2009 | FY 2010 |
|---|---|---|
| Conmed Linvatec | $269.82M | $288.42M |
| Conmed Electrosurgery | $94.96M | $97.21M |
| Conmed Patient Care | $70.98M | $68.28M |
| Conmed Endosurgery | $66.03M | $69.00M |
| Conmed Endoscopic Technologies | $48.94M | $48.52M |
| Total | $550.73M | $571.44M |
Conmed brought in $571.44M from its five segments in fiscal 2010, the year ended December 31, 2010. That was up 3.8% from $550.73M in fiscal 2009. Conmed Linvatec was the largest at $288.42M (50.5%), ahead of Conmed Electrosurgery at $97.21M (17.0%) and Conmed Endosurgery at $69.00M (12.1%). The other two segments brought in $116.80M combined.
Compared with fiscal 2009, Conmed Linvatec grew fastest, up 6.9% to $288.42M, while Conmed Patient Care fell the most, down 3.8% to $68.28M.
United States was Conmed’s largest region in fiscal 2017, bringing in $411.04M of $796.39M (52%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $360.96M | $361.45M | $399.11M | $411.04M | |||||
| All Other Countires | — | — | — | — | |||||
| Emea | $158.04M | $145.57M | $147.99M | $155.85M | |||||
| Asia Pacific | $126.29M | $125.28M | $128.90M | $138.33M | |||||
| Americas (Excluding The United States) | $94.77M | $86.87M | $87.53M | $91.17M | |||||
| Canada | — | — | — | — | |||||
| Australia | — | — | — | — | |||||
| Japan | — | — | — | — | |||||
| United Kingdom | — | — | — | — | |||||
| Total | $740.06M | $719.17M | $763.52M | $796.39M |
Conmed brought in $796.39M from its four regions in fiscal 2017, the year ended December 31, 2017. That was up 4.3% from $763.52M in fiscal 2016. United States was the largest at $411.04M (51.6%), ahead of Emea at $155.85M (19.6%) and Asia Pacific at $138.33M (17.4%). The remaining region, Americas (Excluding The United States), brought in $91.17M.
Compared with fiscal 2016, Asia Pacific grew fastest, up 7.3% to $138.33M. Every region above 2% of revenue grew. From fiscal 2014 to 2017, combined revenue from these regions grew from $740.06M to $796.39M, a compound annual growth rate of 2.5%. United States' share of the total rose from 48.8% to 51.6%.
Conmed (CNMD) reports its revenue by product lines, by business segments and by geography. In fiscal 2017, Orthopedic Surgery was its largest revenue line, bringing in $428.94M (53.9% of the total), followed by General Surgery at $367.45M (46.1%).
Orthopedic Surgery was Conmed's largest revenue line in fiscal 2017, bringing in $428.94M, or 53.9% of the $796.39M total across its two revenue lines.
Conmed Linvatec was Conmed's largest segment in fiscal 2010, bringing in $288.42M, or 50.5% of the $571.44M total across its five segments.
United States was Conmed's largest region in fiscal 2017, bringing in $411.04M, or 51.6% of the $796.39M total across its four regions.
General Surgery grew faster than Orthopedic Surgery in fiscal 2017, up 7.6% from $341.42M to $367.45M. Orthopedic Surgery grew 1.6% to $428.94M.
Every figure comes from Conmed's annual financial filings, as reported. Each line keeps the name Conmed gives it, and years follow its fiscal calendar.
Conmed's revenue by product lines goes back to fiscal 2011, with figures through fiscal 2017. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.